Compare FTV & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTV | WST |
|---|---|---|
| Founded | 2015 | 1923 |
| Country | United States | United States |
| Employees | 18000 | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 17.9B |
| IPO Year | 2015 | 2004 |
| Metric | FTV | WST |
|---|---|---|
| Price | $55.09 | $246.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 7 |
| Target Price | $60.00 | ★ $319.43 |
| AVG Volume (30 Days) | ★ 3.1M | 718.9K |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | ★ 0.43% | 0.37% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | 1.73 | ★ 6.79 |
| Revenue | ★ $6,452,700,000.00 | $2,886,900,000.00 |
| Revenue This Year | $4.73 | $6.73 |
| Revenue Next Year | $3.95 | $6.07 |
| P/E Ratio | ★ $31.93 | $34.94 |
| Revenue Growth | ★ 12.10 | 1.95 |
| 52 Week Low | $46.34 | $187.43 |
| 52 Week High | $76.54 | $322.34 |
| Indicator | FTV | WST |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 52.60 |
| Support Level | $54.71 | $241.57 |
| Resistance Level | $55.98 | $251.73 |
| Average True Range (ATR) | 1.46 | 6.91 |
| MACD | -0.17 | 0.60 |
| Stochastic Oscillator | 29.25 | 69.02 |
Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.2 billion in revenue in 2024.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.